Format

Send to

Choose Destination
Br J Dermatol. 2019 May;180(5):964-965. doi: 10.1111/bjd.17344.

A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus.

Author information

1
Corporal Michael J. Crescenz VAMC, Philadelphia, PA, U.S.A.
2
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, PA, U.S.A.
3
Oklahoma Medical Research Foundation, Oklahoma City, OK, U.S.A.
PMID:
31025748
DOI:
10.1111/bjd.17344

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center